Details for Patent: 9,682,061
✉ Email this page to a colleague
Which drugs does patent 9,682,061 protect, and when does it expire?
Patent 9,682,061 protects KIMYRSA and ORBACTIV and is included in two NDAs.
This patent has seven patent family members in seven countries.
Summary for Patent: 9,682,061
| Title: | Methods of treating bacterial infections using oritavancin |
| Abstract: | The present invention is directed to methods of treating a bacterial infection in a subject through the administration of a therapeutically effective amount of a glycopeptide antibiotic to a subject having a bacterial infection. The effective amount of the glycopeptide antibiotic that is administered to the subject provides a fraction of the glycopeptide antibiotic administered to the subject bound to serum proteins within the subject and within a selected range. |
| Inventor(s): | Lehoux; Dario (Terrebonne, CA), Parr, Jr.; Thomas (Indianapolis, IN), Moeck; Gregory (St. Laurent, CA) |
| Assignee: | THE MEDICINES COMPANY (Parsippany, NJ) |
| Application Number: | 12/740,571 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 9,682,061
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Melinta Therap | KIMYRSA | oritavancin diphosphate | POWDER;INTRAVENOUS | 214155-001 | Mar 12, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS WITH A SINGLE DOSE OF 1200MG ORITAVANCIN OR ITS SINGLE DOSE EQUIVALENT | ⤷ Sign Up | ||||
| Melinta Therap | ORBACTIV | oritavancin diphosphate | POWDER;INTRAVENOUS | 206334-001 | Aug 6, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,682,061
| PCT Information | |||
| PCT Filed | April 26, 2010 | PCT Application Number: | PCT/US2010/032441 |
| PCT Publication Date: | November 11, 2010 | PCT Publication Number: | WO2010/129233 |
International Family Members for US Patent 9,682,061
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2010245097 | ⤷ Sign Up | |||
| Brazil | PI1014767 | ⤷ Sign Up | |||
| Canada | 2760159 | ⤷ Sign Up | |||
| China | 102573882 | ⤷ Sign Up | |||
| European Patent Office | 2424559 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
